Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Gross Margin (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Gross Margin for 3 consecutive years, with 93.84% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 72.0% to 93.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 94.08% through Dec 2025, up 98.0% year-over-year, with the annual reading at 94.08% for FY2025, 98.0% up from the prior year.
  • Gross Margin hit 93.84% in Q4 2025 for Krystal Biotech, down from 95.64% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 97.39% in Q3 2023 to a low of 91.45% in Q2 2024.
  • Historically, Gross Margin has averaged 93.96% across 3 years, with a median of 94.07% in 2025.
  • Biggest five-year swings in Gross Margin: tumbled -537bps in 2024 and later surged 362bps in 2025.
  • Year by year, Gross Margin stood at 93.19% in 2023, then rose by 1bps to 94.57% in 2024, then dropped by -1bps to 93.84% in 2025.
  • Business Quant data shows Gross Margin for KRYS at 93.84% in Q4 2025, 95.64% in Q3 2025, and 92.54% in Q2 2025.